Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696020 · ClinicalTrials.gov registry record · Phase 2
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT00696020 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 360 participants, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00696020, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG tiotropium bromide
- DRUG BI 1744 CL/tiotropium bromide fixed dose combination
- DEVICE Respimat® Inhaler
Study Locations (20)
Florida
- 1237.4.0105 Boehringer Ingelheim Investigational Site - Clearwater
- 1237.4.0110 Boehringer Ingelheim Investigational Site - DeLand
- 1237.4.0117 Boehringer Ingelheim Investigational Site - Tampa
South Carolina
- 1237.4.0111 Boehringer Ingelheim Investigational Site - Charleston
- 1237.4.0106 Boehringer Ingelheim Investigational Site - Spartanburg
- 1237.4.0107 Boehringer Ingelheim Investigational Site - Spartanburg
California
- 1237.4.0118 Boehringer Ingelheim Investigational Site - Riverside
- 1237.4.0103 Boehringer Ingelheim Investigational Site - San Diego
Minnesota
- 1237.4.0120 Boehringer Ingelheim Investigational Site - Edina
- 1237.4.0112 Boehringer Ingelheim Investigational Site - Minneapolis
Texas
- 1237.4.0122 Boehringer Ingelheim Investigational Site - Killeen
- 1237.4.0109 Boehringer Ingelheim Investigational Site - New Braunfels
Colorado
- 1237.4.0115 Boehringer Ingelheim Investigational Site - Wheat Ridge
Idaho
- 1237.4.0104 Boehringer Ingelheim Investigational Site - Coeur d'Alene
Missouri
- 1237.4.0119 Boehringer Ingelheim Investigational Site - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696020
The ClinicalTrials.gov registry entry for NCT00696020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (65% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which tiotropium bromide is the first listed.
NCT00696020 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, South Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00696020 about?
NCT00696020 is a clinical study titled "Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)". The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00696020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2008-06.
What conditions does trial NCT00696020 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00696020?
The interventions under investigation include: tiotropium bromide (DRUG), BI 1744 CL/tiotropium bromide fixed dose combination (DRUG), Respimat® Inhaler (DEVICE).
Who is sponsoring clinical trial NCT00696020?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00696020 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.